Arash Rezazadeh Kalebasty, MD | Authors

Articles

Discussing the Safety Profile of Cabazitaxel in mCRPC

October 20, 2019

Arash Rezazadeh Kalebasty, MD, a hematologist/oncologist and research program director, Urologic Oncology, Norton Cancer Institute, discusses the safety profile of cabazitaxel in the CARD trial, which randomized patients with metastatic castration-resistant prostate cancer to cabazitaxel or one of 2 antiandrogen receptor agents, abiraterone acetate or enzalutamide.